GlassScriptPhysician profile
Sylvia Susana Gray
NPI 1558552737
$6,888.80
in general payments reported to CMS, 2019-2025
36 companies · $2,321 in 2025
The $2,321 reported for 2025 was more than what 85% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $978 · 2020: $1,259 · 2021: $715 · 2022: $362 · 2023: $467 · 2024: $786 · 2025: $2,321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,516 · Travel and Lodging: $1,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,515.72 |
| Travel and Lodging | $1,058.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pylant Medical | $1,519.58 | 2020-2024 | |
| Medical Device Business Services, INC. | $1,170.81 | 2025 | Velys, Actis |
| Sientra, INC. | $698.62 | 2019-2021 | |
| Axogen | $641.60 | 2019-2025 | Avance Nerve Graft, Axoguard Ha+ Nerve Protector, Axoguard Nerve Cap |
| Aroa Biosurgery Incorporated | $321.64 | 2025 | |
| Smith+Nephew, INC. | $288.11 | 2019-2025 | Stravix, Grafix, Hat-Trick |
| Skeletal Dynamics INC | $262.33 | 2024-2025 | Geminus, Ijs, Align |
| Kerecis Limited | $207.17 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Mentor Worldwide LLC | $167.04 | 2019-2022 | |
| Davol INC. | $158.95 | 2022 | |
| Stryker Corporation | $153.63 | 2024 | Gamma |
| Endo Pharmaceuticals INC. | $143.50 | 2021-2023 | Xiaflex |
| Acumed LLC | $122.52 | 2025 | Innate Implant, Acumed |
| Acera Surgical, INC. | $104.21 | 2021-2025 | Restrata Wound Matrix |
| Medartis INC. | $103.13 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tepha INC | $94.83 | 2019 | |
| Polynovo North America LLC | $86.93 | 2023-2025 | Novosorb Btm |
| Exsomed Corporation | $76.76 | 2019 | |
| Abbvie INC. | $58.65 | 2023-2024 | |
| Depuy Synthes Sales INC. | $58.37 | 2019-2021 | |
| Revance Therapeutics, INC. | $54.31 | 2024 | Daxxify |
| Motiva USA, LLC | $49.32 | 2024-2025 | |
| Organogenesis INC. | $39.56 | 2024 | |
| Pacira Therapeutics, INC. | $38.65 | 2019-2021 | |
| Medline Industries LP | $35.99 | 2019 | |
| Dynasplint Systems INC. | $30.51 | 2019 | |
| Zimmer Biomet Holdings, INC. | $26.59 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $25.62 | 2025 | |
| Coopersurgical, INC. | $24.13 | 2024 | Fisherbrand Disposable Liquid Infant Heel Warmer |
| Integra Lifesciences Corporation | $23.89 | 2020 | |
| Medtronic USA, INC. | $21.34 | 2020 | |
| Solventum Corporation | $19.21 | 2025 | Activ.A.C. |
| Sonex Health, INC. | $18.63 | 2021-2023 | Sx-One Microknife |
| Vericel Corporation | $16.78 | 2023 | Maci |
| Bioventus LLC | $14.84 | 2019 | |
| Tela Bio, INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvia Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.